Life expectancy

Cystic Fibrosis Rescued by Reprogramming the Cell’s Secretory Machinery

Retrieved on: 
Wednesday, January 3, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Protein, Cell, Drug design, Human, Publishing, Cystic fibrosis, Diabetes, Doctor of Philosophy, Therapy, Cancer, Life expectancy, Mucus, Mutation, Patent Cooperation Treaty, BioRxiv, DSM-IV codes, Patient, CFTR, Pharmaceutical industry

Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the publishing of a study that brings promise for a cure to cystic fibrosis (CF).

Key Points: 
  • Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the publishing of a study that brings promise for a cure to cystic fibrosis (CF).
  • “We look forward to bringing such new, novel, safe, and curative treatments to market for people living with cystic fibrosis, diabetes, and other secretory disorders.”
    On December 9, 2023, the preprint entitled “ Reprogramming the Cells Secretory Machinery: A Cystic Fibrosis Rescue ” was published on bioRxiv.
  • Results demonstrate that mutation in porosome-associated CFTR also affects other proteins within the porosome secretory machine, thereby reducing mucus secretion.
  • “Our company research has aided in the ability to identify the critical role CFTR plays within the porosome secretory machinery.

Global triggers: why these five big issues could cause significant problems in 2024

Retrieved on: 
Wednesday, January 3, 2024
Workforce, Policy, Social Security, Risk, Death, Viscount Gage, IMF, Instability, GDP, FDI, Population, Health, Disease, Hamas, Life expectancy, War, OECD, Democracy, Unemployment, Republican, Foreign direct investment, Drug

The ramifications of the Ukrainian war echoed beyond the country’s border.

Key Points: 
  • The ramifications of the Ukrainian war echoed beyond the country’s border.
  • Such trends of global power tensions, open war, democratic decline and extreme job market fluctuations are likely to continue in 2024.

Power shifts

  • As the Brics (Brazil, Russia, India, China, South Africa) organisation expands to include Egypt, Ethiopia, Iran, Saudi Arabia and the UAE, its growing economic influence could dramatically change the global balance of power.
  • For countries that have been sanctioned by the west, such as Iran, becoming a Brics member increases their diplomatic options.
  • The Brics’ expansion can also enable members to strengthen their impact by pursuing their political and economic interests more easily.

Global election cycle

  • At the core is the US election where former president Donald Trump is likely to be the Republican candidate.
  • If re-elected, he may continue with his policy of “global engagement abstention” as evidenced by his past willingness to disengage from Nato.
  • Such a stance may weaken the global economic and political system and contribute to the rise of other countries searching for greater global clout.

Heightened tensions in the Middle East

  • The Israel/Hamas war will continue to have repercussions beyond the Middle East.
  • The risk of further escalation of the conflict regionally has intensified after Israel’s air strike in Beirut.
  • The Israel/Gaza war is also likely to discourage investment in the Middle East and disrupt trade routes leading to increasing shipping costs.

China’s economic pressures

  • Recently, China’s economy has been described as a “ticking time bomb” as a result of slow economic growth, high youth unemployment, the property sector crisis, lower Foreign Direct Investment (FDI) and weaker exports.
  • Growth prospects are expected to remain “structurally weaker” with low consumer confidence and spending and declining external demand.

Ageing populations

  • In 2022, Japan, Italy, Finland and Germany were among the countries with the greatest share of populations over 65 years of age and by 2050 it is projected that the list will include Hong Kong, South Korea and Taiwan.
  • By 2050 the percentage of the world’s over 60 population will increase from 12% to 22%.
  • In addition, there is evidence that the ageing of the population affects labour productivity and labour supply.


Jose Caballero does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

GWSO INC Announces Acquisition of AQST USA LLC, Paving the Way for a Clean Energy Revolution

Retrieved on: 
Wednesday, January 3, 2024
Nexus, Entrepreneurship, Partnership, University, Research, Acquisition, Security, Evaluation, Heart, Life expectancy, Oxygen, TPN, Hydrogen, Growth, Renewable energy

Their expertise and groundbreaking work have paved the way for revolutionary advancements in the clean energy sector.

Key Points: 
  • Their expertise and groundbreaking work have paved the way for revolutionary advancements in the clean energy sector.
  • With this acquisition, GWSO INC will integrate the vast knowledge and cutting-edge technology resources of AQST USA LLC to accelerate the development of the hydrogen economy.
  • Joel Smith, Co-Founder and President of AQST USA LLC, added, "This acquisition marks a significant step forward in advancing sustainable energy solutions.
  • GWSO INC's acquisition of AQST USA LLC will undoubtedly reshape the clean energy landscape, offering a game-changing solution for clean hydrogen production.

Is cold water bad for you? What about drinking from the hose or tap? The facts behind 5 water myths

Retrieved on: 
Tuesday, January 2, 2024
Lead, Myth II: Soulblighter, Water, Grain, Dysphagia, Woman, Mineral, Drinking, Glass, Dysentery, Esophageal achalasia, Health, Headache, Drinking water, Bacteria, Migraine, Life expectancy, Plant, University, Microplastics, River, Temperature, Metal, Public, Cholera, Fresh water, University of Queensland, Exercise, Environment, Bottled water

Myth 1: Cold water is bad for you

Key Points: 
  • Myth 1: Cold water is bad for you
    Some recent TikToks have suggested cold water causes health problems by somehow “contracting blood vessels” and “restricting digestion”.
  • Cold water after exercise in summer or hot water to relax in winter won’t make any difference to your overall health.
  • Hot water is generally a better solvent than cold water, so may dissolve metals and minerals from pipes better.
  • It’s better to fill your cup from the cold tap and get hot water for drinks from the kettle.

Global Pet Food Industry Report 2023: A $160+ Billion Market by 2028 - Trends, Share, Size, Growth, Opportunities and Forecasts Featuring Mars Petcare, Nestle, Hill's, and J.M. Smucker - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 2, 2024
Pets, Consumer, Pet, Hormone, SWOT, Health, Legislation, Research, Life expectancy, Knowledge, COVID-19, Infection, Pesticide, Pet industry

The global pet food market size reached US$ 118.9 Billion in 2022.

Key Points: 
  • The global pet food market size reached US$ 118.9 Billion in 2022.
  • This report provides a deep insight into the global pet food industry covering all its essential aspects.
  • Moreover, several pet food associations and federations have introduced strict legislation for the manufacturers to produce safe and high-quality pet food.
  • Global Pet Food Market Drivers:
    As pet food helps in combating skin allergies and infections as well as improving the overall health and life expectancy of pets, the owners are increasingly looking for pet food products that address these health concerns.

VinBrain to Launch AI-centric Solutions to Save Lives and Advance Precision Care at RSNA 2023

Retrieved on: 
Monday, December 4, 2023
Cloud, Liver, Radiology, Microsoft Band, Life expectancy, Stanford University, Cancer, Vingroup, Diagnosis, Microsoft, Hepatocellular carcinoma, Artificial intelligence, SOTA, EDS, Privacy, Exhibition, Knowledge, Fellow, Azure, Health care, Scientific Reports, Medical imaging, Physician, Tuberculosis, HCC, CXR, AI, TACE, HIPAA, Patient, Medicine, NVIDIA, TB, TME, HIS, Learning, Research, R&D, RIS, PACS, EMR, NIST, Health, Graphics processing unit, RSNA, Medical device

Unveiling two impactful AI-centric solutions during the event - DrAid Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone.

Key Points: 
  • Unveiling two impactful AI-centric solutions during the event - DrAid Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone.
  • Expediting interoperability and streamlining, DrAid Enterprise Data Solution (EDS) is hoped to lead the healthcare transformation towards precision care.
  • Dr. Michael C. Muelly, medical partner of VinBrain shared his point of view about clinical practices and values of the solutions during product launch at RSNA 2023.
  • At RSNA 2023, VinBrain also showcased its commitment to providing accessible healthcare in underserved regions with high tuberculosis burden through DrAid for Tuberculosis Screening (CXR Screening).

Fraser Institute News Release: Estonian incomes, living standards, life expectancy improved dramatically after transition to market democracy

Retrieved on: 
Monday, December 18, 2023
Public policy, Bangladesh Technical Education Board, Government, World war, Ageing, Life expectancy, Fraser Institute, Road, Poverty, Food, Socialism, Entrepreneurship

When the Soviet Union collapsed in 1991, Estonia began a dramatic transformation back to a market democracy.

Key Points: 
  • When the Soviet Union collapsed in 1991, Estonia began a dramatic transformation back to a market democracy.
  • In 1993, the average Estonian could expect to die more than nine years earlier than the average resident of high-income countries.
  • Before the transition, the average Estonian could buy one-fourth as much food on his annual salary as the average Finn.
  • “Some Canadians support an economic system that impoverished Estonians and shortened their life expectancy,” Mitchell said.

Slalom Collaborates with AWS and DIPG DMG Research Funding Alliance to Fight Childhood Brain Cancer with Data

Retrieved on: 
Thursday, December 14, 2023
Neoplasm, AWS, Diffusion, Caregiver, Mevalonate pathway, DMG, Research, Slalom, Parent, Disease, Cancer, Life expectancy, Brain, Death, Diffuse intrinsic pontine glioma, Ward, Child, DIPG, Central nervous system, Diagnosis, Amazon Web Services, Pharmaceutical industry

SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- In a united effort to combat childhood brain cancer, Slalom has worked with Amazon Web Services (AWS) and the DIPG DMG Research Funding Alliance (DDRFA) to create the DIPG One Link , a unique centralized resource hub that helps accelerate research and awareness of Diffuse Intrinsic Pontine Glioma (DIPG), also known as Diffuse Midline Glioma (DMG).

Key Points: 
  • SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- In a united effort to combat childhood brain cancer, Slalom has worked with Amazon Web Services (AWS) and the DIPG DMG Research Funding Alliance (DDRFA) to create the DIPG One Link , a unique centralized resource hub that helps accelerate research and awareness of Diffuse Intrinsic Pontine Glioma (DIPG), also known as Diffuse Midline Glioma (DMG).
  • DIPG DMG is a rare and often fatal form of childhood brain cancer with limited treatment options and scarce research data.
  • “As parents fighting DIPG alongside our children we discovered significant gaps in the system which expects parents to navigate their child’s care.
  • With AWS, Slalom executed the research, design, and development of the DIPG One Link website to support those looking for information to fight DIPG DMG.

ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.

Retrieved on: 
Monday, December 4, 2023
ALS, Peripheral neuropathy, Toxicology, HDAC6, Research, Polyneuropathy, Disease, IPSC, CMT, ALS Association, Life expectancy, Respiratory failure, USD, Genomics, Death, Systemic disease, Proteostasis, Neurodegenerative disease, Axonal transport, Diagnosis, Safety, Pharmaceutical industry

The Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selective HDAC6 inhibitor, for amyotrophic lateral sclerosis (ALS).

Key Points: 
  • The Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selective HDAC6 inhibitor, for amyotrophic lateral sclerosis (ALS).
  • Dr. Jordi Xaus, Oryzon’s CSO, said: “It is an honor to have the support of the ALS Association.
  • Established in 1985, the ALS Association is the largest philanthropic funder of ALS research in the world.
  • The Association is working to make ALS a livable disease while urgently searching for new treatments and a cure.

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Retrieved on: 
Friday, December 1, 2023
Quality of life, Protein, GLB1, GM1, Disorder, PLOS, Brain, Muscle weakness, Doctor of Philosophy, Research, Therapy, Glycogen storage disease, Life expectancy, DSM-IV codes, Paratriathlon, Dystonia, Protein folding, Patient, HaloTag, Pharmaceutical industry

BETHESDA, Md., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators that demonstrate therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage disorders (LSDs), including GM1 gangliosidosis. The study, “Validation of a highly sensitive HaloTag-based assay to evaluate the potency of a novel class of allosteric β-Galactosidase correctors,” was published in PLOS ONE.

Key Points: 
  • The study, “Validation of a highly sensitive HaloTag-based assay to evaluate the potency of a novel class of allosteric β-Galactosidase correctors,” was published in PLOS ONE.
  • GM1-gangliosidosis is an inherited, progressive disorder characterized by the degeneration of brain and spinal cord cells, leading to muscle weakness, skeletal abnormalities, dystonia, and vision problems.
  • Mutations in the GLB1 gene significantly reduce the activity and function of the lysosomal hydrolase enzyme β-galactosidase (β-Gal) due to protein misfolding.
  • Additionally, there are no available disease-modifying treatments for GM1 gangliosidosis, with available therapies only focused on reducing symptoms and improving quality of life.